Eli Lilly selects Pennsylvania for $3.5bn obesity drugs manufacturing site
Eli Lilly has chosen Pennsylvania to house a new $3.5bn manufacturing facility that will produce a forthcoming wave of new …
Post
-
-
Amgen hands back eczema drug to Kyowa Kirin despite positive late-stage data
Amgen is handing back the rights of its successful in-licensed atopic dermatitis (AD) asset, rocatinlimab, to Kyowa Kirin. In a statement …
-
CHMP grants positive opinion for J&J’s Akeega use
Johnson & Johnson (J&J) has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for …
-
CIRM unveils RAPID funding programme for rare diseases
The California Institute for Regenerative Medicine (CIRM) in the US has approved the Rare Disease Acceleration Platform and Innovation and …
-
FDA’s new scheme to boost US manufacturing commences despite uncertainty
The US Food and Drug Administration (FDA) will start accepting applications for the new PreCheck scheme that will streamline the …
-
Sanofi touts strong new launch sales amid looming Dupixent patent expiry
Sanofi is making successful strides to restock its pipeline and shore up revenue streams amid the looming patent expiry of …
-
AstraZeneca signs $18.5bn weight loss drug deal with CSPC
AstraZeneca has outlaid up to $18.5bn in a licensing deal with China-based CSPC Pharmaceuticals to develop longer lasting weight-loss drugs, …
-
IQVIA and Boehringer Ingelheim collaborate on therapeutic data transformation
IQVIA has announced a strategic, long-term partnership with Boehringer Ingelheim focused on strengthening data capabilities across therapeutic areas. As part of …
-
Repertoire and Lilly join hands on autoimmune disease therapies
Repertoire Immune Medicines has collaborated with Eli Lilly and Company to develop tolerising therapies to treat several autoimmune diseases. The partnership …
-
AstraZeneca pours $15bn into Chinese R&D and manufacturing operations
Pharma giant AstraZeneca is pledging $15bn to fund an R&D and manufacturing capacity expansion in China – marking a significant …
-
Roche’s 2025 profit blunted by weakened US dollar
Roche’s adjusted operating profit rose by a lower-than-expected 5% in 2025, due to the weakened US dollar, despite the drugmaker …
-
Sensorion announces $71.9m reserved offering to expand gene therapy pipeline
Sensorion has announced a €60m ($71.9m) reserved offering through the issuance of 214,285,714 new ordinary shares at €0.28 per share …
-
FDA grants breakthrough status to Biogen’s litifilimab for CLE
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Biogen’s litifilimab (BIIB059) for cutaneous lupus erythematosus …
-
Eli Lilly outlays $1.12bn for hearing loss gene therapy partnership
In a move that continues a recent bolstering of its gene therapy pipeline, Eli Lilly has signed a global research …
-
The importance of real-world evidence in transforming healthcare decision-making
Over the last 20 years, US healthcare has shifted to a value-based system, with payers and healthcare providers being challenged …
